[Response to the COVID-19 Health Crisis from a Gender Perspective: Lessons Learned].

Autor: Llobera Ribera C; Departamento de Enfermería Comunitaria, Medicina Preventiva y Salud Pública e Historia de la Ciencia, Universidad de Alicante, Alicante, España. Electronic address: chlloberaribera@gmail.com., Ruiz-Cantero MT; Grupo de Investigación de Salud Pública, Universidad de Alicante, Alicante, España; CIBER de Epidemiología y Salud Pública (CIBERESP), España., García-Calvente M; Escuela Andaluza de Salud Pública, Granada, España; Instituto de Investigación Biosanitaria de Granada, Granada, España., Torrell G; Institut Català de la Salut, Barcelona, España., González Bermejo D; Agencia Española de Medicamentos y Productos Sanitarios, Madrid, España., Olmedo C; Programa de Vacunación, Dirección General de Salud Pública, Ministerio de Sanidad, Madrid, España., Moatassim E; Dirección de Atención y Evaluación Sanitaria, Servicio de Salud del Principado de Asturias, Oviedo, España., Bacigalupe A; Grupo de Investigación en Determinantes Sociales de la Salud y Cambio Demográfico, Leioa (Bizkaia), España; Departamento de Sociología y Trabajo Social, Universidad del País Vasco, Leioa (Bizkaia), España.

Publikováno v: Gaceta sanitaria [Gac Sanit] 2024 Feb 14; Vol. 38, pp. 102358. Date of Electronic Publication: 2024 Feb 14.

Selective Serotonin Reuptake Inhibitors and Risk of Noncardioembolic Ischemic Stroke: A Nested Case-Control Study.

Autor: Alqdwah-Fattouh R; Unit of Epidemiology and Public Health. School of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain (R.A.-F., F.B.)., Rodríguez-Martín S; Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain (S.R.-M., D.B.-H., E.F.-A., A.R.M., F.J.d.A.).; Department of Biomedical Sciences (Pharmacology Sector), School of Medicine, University of Alcalá (IRYCIS), Alcalá de Henares, Madrid, Spain (S.R.-M., D.B.-H., E.F.-A., A.R.M., F.J.d.A.)., Barreira-Hernández D; Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain (S.R.-M., D.B.-H., E.F.-A., A.R.M., F.J.d.A.).; Department of Biomedical Sciences (Pharmacology Sector), School of Medicine, University of Alcalá (IRYCIS), Alcalá de Henares, Madrid, Spain (S.R.-M., D.B.-H., E.F.-A., A.R.M., F.J.d.A.)., Izquierdo-Esteban L; Stroke Unit, Department of Neurology, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain (L.I.-E.)., Gil M; Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices, Madrid, Spain (M.G., D.G.-B.)., González-Bermejo D; Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices, Madrid, Spain (M.G., D.G.-B.)., Fernández-Antón E; Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain (S.R.-M., D.B.-H., E.F.-A., A.R.M., F.J.d.A.).; Department of Biomedical Sciences (Pharmacology Sector), School of Medicine, University of Alcalá (IRYCIS), Alcalá de Henares, Madrid, Spain (S.R.-M., D.B.-H., E.F.-A., A.R.M., F.J.d.A.)., Rodríguez-Miguel A; Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain (S.R.-M., D.B.-H., E.F.-A., A.R.M., F.J.d.A.).; Department of Biomedical Sciences (Pharmacology Sector), School of Medicine, University of Alcalá (IRYCIS), Alcalá de Henares, Madrid, Spain (S.R.-M., D.B.-H., E.F.-A., A.R.M., F.J.d.A.)., García-Lledó A; Department of Cardiology, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain (A.G.-L.).; Department of Medicine, School of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain (A.G.-L.)., Bolúmar F; Unit of Epidemiology and Public Health. School of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain (R.A.-F., F.B.).; Department of Epidemiology and Biostatistics, Graduate School of Public Health, City University of New York (F.B.).; CIBERESP, Spain (F.B.)., de Abajo FJ; Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain (S.R.-M., D.B.-H., E.F.-A., A.R.M., F.J.d.A.).; Department of Biomedical Sciences (Pharmacology Sector), School of Medicine, University of Alcalá (IRYCIS), Alcalá de Henares, Madrid, Spain (S.R.-M., D.B.-H., E.F.-A., A.R.M., F.J.d.A.).

Publikováno v: Stroke [Stroke] 2022 May; Vol. 53 (5), pp. 1560-1569. Date of Electronic Publication: 2022 Feb 03.

Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses

Autor: Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B

Publikováno v: PLOS MEDICINE
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Background Medications aimed at inhibiting the renin-angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0e234d8f0426e3b35bda76c778c374f2
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1215

Drug utilization study on immediate release Fentanyl in Spain. Prevalence, incidence, and indication.

Autor: González-Bermejo D; Pharmacoepidemiology and Pharmacovigilance Division. Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Rayón-Iglesias P; Pharmacoepidemiology and Pharmacovigilance Division. Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Rodríguez-Pascual A; Pharmacoepidemiology and Pharmacovigilance Division. Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Álvarez-Gutiérrez A; Pharmacoepidemiology and Pharmacovigilance Division. Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Fernández-Dueñas A; Pharmacoepidemiology and Pharmacovigilance Division. Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Montero-Corominas D; Pharmacoepidemiology and Pharmacovigilance Division. Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Huerta-Álvarez C; Pharmacoepidemiology and Pharmacovigilance Division. Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain.

Publikováno v: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2021 Mar; Vol. 30 (3), pp. 371-378. Date of Electronic Publication: 2020 Sep 14.

Clinical-Epidemiological Profile of Patients Initiating Intensive Statin Therapy for the Secondary Prevention of Vascular Disease in Spain

Autor: Macías Saint-Gerons D, de la Fuente Honrubia C, González Bermejo D, Montero D, Gil MJ, Salvador Sanz A, de Andrés-Trelles F, Catalá-López F

Publikováno v: REVISTA ESPANOLA DE SALUD PUBLICA
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Background: The new recommendations regarding the utilization of high potency statins (intensive therapy) for the treatment of cardiovascular disease have been based on the extrapolation of data coming from clinical trials. The objective is to descri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::b72f5ca53dda8d07779a6a70af6acfa2
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1535